[go: up one dir, main page]

WO2025131618A1 - Cassette pour dispositif d'administration de médicament - Google Patents

Cassette pour dispositif d'administration de médicament Download PDF

Info

Publication number
WO2025131618A1
WO2025131618A1 PCT/EP2024/083997 EP2024083997W WO2025131618A1 WO 2025131618 A1 WO2025131618 A1 WO 2025131618A1 EP 2024083997 W EP2024083997 W EP 2024083997W WO 2025131618 A1 WO2025131618 A1 WO 2025131618A1
Authority
WO
WIPO (PCT)
Prior art keywords
shell
medicament
medicament bag
bag
cassette
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/EP2024/083997
Other languages
English (en)
Inventor
Lukas Bannwart
Samuel Wyler
Diana KOVACEVIC
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SHL Medical AG
Original Assignee
SHL Medical AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SHL Medical AG filed Critical SHL Medical AG
Publication of WO2025131618A1 publication Critical patent/WO2025131618A1/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A61J1/16—Holders for containers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
    • A61J1/10—Bag-type containers

Definitions

  • the present disclosure relates to a cassette for a medicament delivery device.
  • the disclosure relates to a cassette containing a medicament bag which may be pressurised for medicament delivery.
  • Flexible medicament bags containing a liquid drug are used in various manually or automatically operated medicament delivery devices.
  • the flexible nature of the medicament bag may in some cases lead to a collapse or deformation of the medicament bag during filling or during medicament delivery and thus hinder completely filling or emptying the medicament bag. This is of particular importance for higher volume bags.
  • cassettes according to the prior art hold the medicament bag at the seam in order to provide tension to the bag and avoid deformation to improve filling and emptying of the bag.
  • the solutions according to the prior art may not fully account for various bag shapes as well as the shape change during the filling and medicament delivery process.
  • the present invention has thus been made to remedy the above shortcomings.
  • the present invention may allow for a certain guided movement of the medicament bag within the cassette, therefore facilitating filling and ensuring a complete discharging of the drug.
  • the present disclosure relates to a cassette for a medicament delivery device, comprising a shell, a medicament bag configured to receive a fluid medicament, wherein the medicament bag comprises a port in fluid connection with an interior of the medicament bag.
  • the medicament bag is enclosed by the shell.
  • a gap is formed inside the shell configured to receive a peripheral part of the medicament bag and configured to allow the peripheral part of the medicament bag to move along the gap.
  • a height of the gap is greater than a height (thickness) of the peripheral part of the medicament bag.
  • the gap is formed at least laterally on two opposing sides of the shell, respectively.
  • the gap is formed at least on two lateral opposing sides of the shell.
  • the shell comprises an upper shell and a lower shell.
  • the gap is configured to allow the peripheral part to move in a first axis direction and/or second axis direction while substantially blocking movement in a third axis direction.
  • FIG. i shows an exploded view of a cassette according to an embodiment of the present disclosure.
  • FIGS. 2A to 2E show different stages of the assembly of a cassette according to an embodiment of the present disclosure.
  • the cassette comprises a shell 31, 32 and a medicament bag 1 configured to receive a fluid medicament.
  • the medicament bag 1 comprises a port 2 in fluid connection with an interior of the medicament bag 1.
  • the medicament bag 1 is enclosed by the shell 31, 32. That is, the medicament bag 1 may be located in an internal space or volume of the shell 31, 32.
  • a gap 33 is formed inside the shell 31, 32 configured to receive a peripheral part 11 of the medicament bag 1 and configured to allow the peripheral part 11 of the medicament bag 1 to move or slide along the gap 33.
  • the gap 33 maybe provided on lateral sides si, S2 inside the shell 31, 32.
  • the lateral sides si, S2 may refer to opposing sides.
  • the lateral sides si, S2 may refer to opposing sides extending along the longitudinal direction of the device (x-axis).
  • the lateral sides si, S2 may extend parallel to a filling direction of the medicament bag 11 via the port 2.
  • the lateral sides si, S2 may refer to the sides not comprising the port 2 and not opposing the port 2.
  • the peripheral part 11 may refer to at least a part of the circumference of the medicament bag 1.
  • the peripheral part 11 may relate to the maximum extension of the medicament bag 1 in the lateral direction (positive/negative y-axis direction) and/or in the longitudinal direction (positive-negative x-axis direction).
  • a medicament bag 1 comprises a circumferential (welded) seam connecting and sealing two plastic sheets to another such that an internal volume for receiving a medicament is formed.
  • the seam may constitute the peripheral part n.
  • the port 2 may also be welded into the medicament bag’s i seam.
  • Movement of the medicament bag i, in particular the peripheral part n, is possible along a longitudinal extension of the gap 33. That is, the peripheral part 11 may be able to move in the positive and negative x-axis direction indicated in the figures, depending on a filling state of the medicament bag 1.
  • the medicament bag 1 depicted in the figures is a wavy or zig-zag shaped medicament bag 1 but the disclosure is not limited thereto.
  • a wavy bag may improve exploitation of the internal volume of the medicament bag 1 by reducing or eliminating dead space (i.e., may ensure and facilitate proper filling of the bag 1) and may also ensure completely emptying the medicament bag 1 during medicament delivery. Moreover, bending or kinking of the medicament bag 1 may be avoided.
  • Such wavy shape may comprise one or more bumps that may be uniformly or irregularly distributed along a circumference of the medicament bag 1.
  • the wave may be a substantially sinusoidal wave, triangular wave or asymmetrical wave.
  • the medicament bag 1 may have a round shape, a rectangular shape or a substantially rectangular shape with at least one curved side (tapered).
  • the present disclosure can be applied irrespective of an outer shape of the medicament bag 1.
  • more or less parts/ area of the medicament bag’s circumference forms the peripheral part 11 received in the gap 33.
  • the peripheral part 11 may refer to the maximum lateral/longitudinal extension of the medicament bag i (such as the three tips per side of the medicament bag’s i waves shown in FIGS, i and 2B).
  • FIGS. 1 and 2B also show an optional channel 12 provided in the medicament bag i.
  • Said channel 12 may extend along a centre line of the medicament bag 1 (which may correspond to the centre line of the shell 31, 32).
  • the channel 12 maybe pre-formed and extend in the height direction (z-axis).
  • the channel may be symmetrical with respect to the x-y plane or provided only in the positive or negative z-axis direction.
  • said channel may avoid that the two films of the medicament bag 1 contact each other (at least in the area of the channel 12) and block further removal of the fluid from the medicament bag 1.
  • the medicament can be fully extracted from the medicament bag 1 since the film layers to cannot adhere to one another over the complete area of the bag 1.
  • the channel 12 may collapse by pressure, thus completely pushing out the remaining fluid.
  • the channel 12 may substantially extend from the port 2 to the end of the bag 1 opposite the port 2 (in the longitudinal direction, x-axis).
  • shape, diameter, cross-section and longitudinal extension may vary depending on the concrete requirements.
  • the cassette according to an embodiment may comprise an upper shell 31 and a lower shell 32 as exemplarily shown in the exploded view of FIG. 1.
  • a medicament bag 1 is configured to receive a fluid medicament.
  • the medicament bag 1 comprises a port 2 in fluid connection with an interior of the medicament bag 1.
  • the medicament bag 1 is enclosed by the upper shell 31 and the lower shell 32.
  • a gap 33 (slot) is formed between the upper shell 31 and the lower shell 32. Said gap 33 is configured to receive a peripheral part 11 of the medicament bag 1 and is configured to allow the peripheral part 11 of the medicament bag 1 to move along the gap 33.
  • the gap 33 may allow the peripheral part 11 to move in a longitudinal direction with respect to the port 2.
  • the terms upper shell 31 and lower shell 32 are not to be understood as limiting or requiring a certain orientation of the shells/ shell parts or the cassette and can thus be used interchangeably.
  • the shell parts may also be referred to as a first shell 31 and a second shell 32.
  • the shell parts 31, 32 may substantially be mirror symmetric or, as noted above, identical/the same part. That is, the shell parts 31, 32 maybe integrally formed or formed as a monolithic element and the cassette may thus comprise a single shell part configured to receive the medicament bag 1.
  • the detailed description exemplarily refers to an upper shell 31 and lower shell 32 but the present disclosure is not limited thereto.
  • the upper shell 31 and the lower shell 32 may form an outer appearance of the cassette.
  • a height g of the gap may be greater than a height b (thickness) of the peripheral part 11 of the medicament bag 1 (see FIG. 3B).
  • the height g may herein refer to a distance between upper and lower shell 31, 32 in the gap region, i.e., the z-direction in the figures.
  • the cassette may also comprise an air inlet port 4 formed between the upper shell 31 and the lower shell 32.
  • the air inlet port 4 may be used to pressurise an interior of the cassette, i.e., the space between the upper shell 31 and the lower shell 32, e.g., by attaching a driving system comprising an air pump (not shown). Thereby, a fluid (e.g., a medicament) contained in the medicament bag 1 may be emptied through the port.
  • a fluid e.g., a medicament
  • the cassette may further comprise an air inlet port 4 configured for connecting an air pump for pressurising the space between the upper shell 31 and the lower shell 32.
  • the air inlet port 4 may, e.g., comprise a one-way valve sealing an interior of the cassette or may be open but seal the interior once a driving system is connected to the cassette. That is, depending on the driving system to be attached, the cassette may be fully sealed or sealed on all sides apart from the air inlet port 4.
  • the cassette further comprises a shroud 5 (removably or fixedly) connected to the upper shell 31 and the lower shell 32.
  • the shroud 5 is also connected in an air-tight manner to the upper shell 31 and the lower shell 32.
  • the air inlet port 4 may be provided in the shroud 5.
  • the shroud 5 may allow attachment of a driving system to the cassette for pressurising the interior of the cassette and for allowing medicament delivery.
  • the shroud 5 is shown opposite the port 2 but the present disclosure is not limited to this configuration and the shroud 5 (and/ or the air intake port 2) may be provided on any side of the cassette.
  • the shroud function can also be integrated in any one of the shell parts 31, 32 or the port 2.
  • FIG. 3B is a partial sectional view along the line E-E of FIG. 3A showing the gap 33 formed between the upper shell 31 and the lower shell 32.
  • the height g of the gap 33 maybe larger than the height/thickness b of the peripheral part/seam 11 of the medicament bag 1.
  • the upper shell 31 comprises a groove 35 and the lower shell 32 comprises a corresponding tongue 34 configured to be received in the groove 35, or vice versa.
  • the groove 35 and the tongue 34 substantially extend around the periphery of the upper shell 31 and the lower shell 32, respectively (apart from the port 2 region and air inlet port 4 region).
  • the contact surfaces between the upper shell 31 and the lower shell 32 may also have another engaging shape or be flat.
  • the periphery or parts of the periphery of the medicament bag 1 may be guided in the gap 33 without being held. That is, the gap 33 may allow movement of the medicament bag 1, in particular its peripheral region, in the longitudinal and the lateral direction (x-axis/y-axis).
  • the term periphery/ peripheral region may refer to a seam or sealing region of the medicament bag 1, generally extending around the medicament bag 1 except for the port 2 region.
  • the gap 33 may be particularly useful for filling and emptying of the medicament bag 1.
  • its height extension z- axis direction
  • the sides of the bag 1 may contract to compensate for the change of internal volume. That is, during filling, the medicament bag 11 may contract in the x-axis direction and/or y-axis direction. Consequently, the medicament bag 1 may expand in the x-axis direction and/or y-axis direction when the medicament bag 1 is emptied. This contraction or expansion may then lead to a (sliding) movement of the peripheral part 11 in the gap 33.
  • the medicament bag 1 may be able to move while still being guided, thus allowing complete filling of the medicament bag 1 and thus using its full capacity. This may particularly apply to the longitudinal direction. The same applies to the emptying process in which the medicament bag 1 may also change its outer shape in the reverse direction.
  • the gap 33 can be easily adjusted to the needs (dimension, surface, parallelism), e.g., by using an injection moulding process.
  • the medicament bag 1 may be positioned and supported by the cassette/ vessel but is not fixed in the longitudinal direction with respect to the port 2.
  • a medicament bag 1 having a zig-zag shape or wave shape is shown as an example. This shows that the present disclosure is also applicable to irregularly shaped medicament bags 1 where only parts of the periphery are guided in the gap 33. However, the present disclosure may in principle be applied to any sort and shape of medicament bag 1 and cassette.
  • the delivery devices described herein can be used for the treatment and/ or prophylaxis of one or more of many different types of disorders.
  • Exemplary disorders include, but are not limited to: rheumatoid arthritis, inflammatory bowel diseases (e.g. Crohn’s disease and ulcerative colitis), hypercholesterolaemia and/or dyslipidemia, cardiovascular disease, diabetes (e.g.
  • psoriasis psoriatic arthritis
  • spondyloarthritis hi dradenitis suppurativa
  • Sjogren's syndrome migraine, cluster headache, multiple sclerosis, neuromyelitis optica spectrum disorder, anaemia, thalassemia, paroxysmal nocturnal hemoglobinuria, hemolytic anaemia, hereditary angioedema, systemic lupus erythematosus, lupus nephritis, myasthenia gravis, Behqet's disease, hemophagocytic lymphohistiocytosis, atopic dermatitis, retinal diseases (e.g., age-related macular degeneration, diabetic macular edema), uveitis, infectious diseases, bone diseases (e.g., osteoporosis, osteopenia), asthma, chronic obstructive pulmonary disease, thyroid eye disease, nasal polyps, transplant, acute hypog
  • Exemplary types of drugs that could be included in the delivery devices described herein include, but are not limited to, small molecules, hormones, cytokines, blood products, enzymes, vaccines, anticoagulants, immunosuppressants, antibodies, antibody-drug conjugates, neutralizing antibodies, reversal agents, radioligand therapies, radioisotopes and/or nuclear medicines, diagnostic agents, bispecific antibodies, proteins, fusion proteins, peptibodies, polypeptides, pegylated proteins, protein fragments, nucleotides, protein analogues, protein variants, protein precursors, protein derivatives, chimeric antigen receptor T cell therapies, cell or gene therapies, oncolytic viruses, or immunotherapies.
  • Exemplary drugs that could be included in the delivery devices described herein include, but are not limited to, immuno-oncology or bio-oncology medications such as immune checkpoints, cytokines, chemokines, clusters of differentiation, interleukins, integrins, growth factors, coagulation factors, enzymes, enzyme inhibitors, retinoids, steroids, signaling proteins, pro- apoptotic proteins, anti-apoptotic proteins, T-cell receptors, B-cell receptors, or costimulatory proteins.
  • immuno-oncology or bio-oncology medications such as immune checkpoints, cytokines, chemokines, clusters of differentiation, interleukins, integrins, growth factors, coagulation factors, enzymes, enzyme inhibitors, retinoids, steroids, signaling proteins, pro- apoptotic proteins, anti-apoptotic proteins, T-cell receptors, B-cell receptors, or costimulatory proteins.
  • Exemplary drugs that could be included in the delivery devices described herein include, but are not limited to, those exhibiting a proposed mechanism of action, such as human epidermal growth factor receptor 2 (HER-2) receptor modulators, interleukin (IL) modulators, interferon (IFN) modulators, complement modulators, glucagon-like peptide-i (GLP-i) modulators, glucose-dependent insulinotropic polypeptide (GIP) modulators, cluster of differentiation 38 (CD38) modulators, cluster of differentiation 22 (CD22) modulators, Ci esterase modulators, bradykinin modulators, C-C chemokine receptor type 4 (CCR4) modulators, vascular endothelial growth factor (VEGF) modulators, B-cell activating factor (BAFF), P-selectin modulators, neonatal Fc receptor (FcRn) modulators, calcitonin gene-related peptide (CGRP) modulators, epidermal growth factor receptor (EGFR) modulators, cluster of differentiation 79B (CD79B
  • Exemplary drugs that could be included in the delivery devices described herein include, but are not limited to: etanercept, abatacept, adalimumab, evolocumab, exenatide, secukinumab, erenumab, galcanezumab, fremanezumab-vfrm, alirocumab, methotrexate (amethopterin), tocilizumab, interferon beta-ia, interferon beta-ib, peginterferon beta-ia, sumatriptan, darbepoetin alfa, belimumab, sarilumab, semaglutide, dupilumab, reslizumab, omalizumab, glucagon, epinephrine, naloxone, insulin, amylin, vedolizumab, eculizumab, ravulizumab, crizanlizuma
  • Exemplary drugs that could be included in the delivery devices described herein may also include, but are not limited to, oncology treatments such as ipilimumab, nivolumab, pembrolizumab, atezolizumab, durvalumab, avelumab, cemiplimab, rituximab, trastuzumab, ado-trastuzumab emtansine, fam-trastuzumab deruxtecan-nxki, pertuzumab, transtuzumab-pertuzumab, alemtuzumab, belantamab mafodotin-blmf, bevacizumab, blinatumomab, brentuximab vedotin, cetuximab, daratumumab, elotuzumab, gemtuzumab ozogamicin, 90-Yttrium-ibritumo
  • Exemplary drugs that could be included in the delivery devices described herein include “generic” or biosimilar equivalents of any of the foregoing, and the foregoing molecular names should not be construed as limiting to the “innovator” or “branded” version of each, as in the non-limiting example of innovator medicament adalimumab and biosimilars such as adalimumab- afzb, adalimumab-atto, adalimumab-adbm, and adalimumab-adaz.
  • Exemplary drugs that could be included in the delivery devices described herein also include, but are not limited to, those used for adjuvant or neoadjuvant chemotherapy, such as an alkylating agent, plant alkaloid, antitumor antibiotic, antimetabolite, or topoisomerase inhibitor, enzyme, retinoid, or corticosteroid.
  • adjuvant or neoadjuvant chemotherapy such as an alkylating agent, plant alkaloid, antitumor antibiotic, antimetabolite, or topoisomerase inhibitor, enzyme, retinoid, or corticosteroid.
  • Exemplary chemotherapy drugs include, by way of example but not limitation, 5-fluorouracil, cisplatin, carboplatin, oxaliplatin, doxorubicin, daunorubicin, idarubicin, epirubicin, paclitaxel, docetaxel, cyclophosphamide, ifosfamide, azacitidine, decitabine, bendamustine, bleomycin, bortezomib, busulfan, cabazitaxel, carmustine, cladribine, cytarabine, dacarbazine, etoposide, fludarabine, gemcitabine, irinotecan, leucovorin, melphalan, methotrexate, pemetrexed, mitomycin, mitoxantrone, temsirolimus, topotecan, valrubicin, vincristine, vinblastine, or vinorelbine.
  • Exemplary drugs that could be included in the delivery devices described herein also include, but are not limited to, analgesics (e.g., acetaminophen), antipyretics, corticosteroids (e.g. hydrocortisone, dexamethasone, or methylprednisolone), antihistamines (e.g., diphenhydramine or famotidine), antiemetics (e.g., ondansetron), antibiotics, antiseptics, anticoagulants, fibrinolytics (e.g., recombinant tissue plasminogen activator [r-TPA]), antithrombolytics, or diluents such as sterile water for injection (SWFI), 0.9% Normal Saline, 0.45% normal saline, 5% dextrose in water, 5% dextrose in 0.45% normal saline, Lactated Ringer’s solution, Heparin Lock Flush solution, loo U/mL Heparin Lock Flush Solution,
  • compositions including, but not limited to, any drug described herein are also contemplated for use in the delivery devices described herein, for example pharmaceutical formulations comprising a drug as listed herein (or a pharmaceutically acceptable salt of the drug) and a pharmaceutically acceptable carrier.
  • Such formulations may include one or more other active ingredients (e.g., as a combination of one or more active drugs), or may be the only active ingredient present, and may also include separately administered or co-formulated dispersion enhancers (e.g. an animal-derived, human-derived, or recombinant hyaluronidase enzyme), concentration modifiers or enhancers, stabilizers, buffers, or other excipients.
  • Exemplary drugs that could be included in the delivery devices described herein include, but are not limited to, a multi-medication treatment regimen such as AC, Dose-Dense AC, TCH, GT, EC, TAC, TC, TCHP, CMF, FOLFOX, mF0LF0X6, mFOLFOXy, FOLFCIS, CapeOx, FLOT, DCF, FOLFIRI, FOLFIRINOX, FOLFOXIRI, IROX, CHOP, R-CHOP, RCHOP-21, Mini- CHOP, Maxi-CHOP, VR-CAP, Dose-Dense CHOP, EPOCH, Dose-Adjusted EPOCH, R-EPOCH, CODOX-M, IVAC, HyperCVAD, R-HyperCVAD, SC- EPOCH-RR, DHAP, ESHAP, GDP, ICE, MINE, CEPP, CDOP, GemOx, CEOP, CEPP, CHOEP, CHP, GCVP, DHA

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Abstract

La présente invention concerne une cassette pour un dispositif d'administration de médicament, comprenant une coque, un sac de médicament conçu pour recevoir un médicament fluide, le sac de médicament comprenant un orifice en communication fluidique avec un intérieur du sac de médicament. Le sac de médicament est enfermé par la coque. Un espace est formé à l'intérieur de la coque conçu pour recevoir une partie périphérique du sac de médicament et conçu pour permettre à la partie périphérique du sac de médicament de se déplacer le long de l'espace.
PCT/EP2024/083997 2023-12-18 2024-11-28 Cassette pour dispositif d'administration de médicament Pending WO2025131618A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202363611235P 2023-12-18 2023-12-18
US63/611,235 2023-12-18
US202463702687P 2024-10-03 2024-10-03
US63/702,687 2024-10-03

Publications (1)

Publication Number Publication Date
WO2025131618A1 true WO2025131618A1 (fr) 2025-06-26

Family

ID=93796991

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2024/083997 Pending WO2025131618A1 (fr) 2023-12-18 2024-11-28 Cassette pour dispositif d'administration de médicament

Country Status (1)

Country Link
WO (1) WO2025131618A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013053011A1 (fr) * 2011-10-12 2013-04-18 Bluechiip Limited Cassette de stockage
US20180021218A1 (en) * 2016-01-29 2018-01-25 Entergris, Inc. Bag assembly sterilizable by gamma irradiation
US20200237620A1 (en) * 2017-10-06 2020-07-30 Sartorius Stedim Fmt Sas Protective containers for biopharmaceutical liquid bags
US20200253823A1 (en) * 2019-02-12 2020-08-13 Amgen Inc. Dosing systems and approaches
CN116602866A (zh) * 2023-04-24 2023-08-18 中国人民解放军陆军军医大学第二附属医院 一种可调节的输血袋固定装置

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013053011A1 (fr) * 2011-10-12 2013-04-18 Bluechiip Limited Cassette de stockage
US20180021218A1 (en) * 2016-01-29 2018-01-25 Entergris, Inc. Bag assembly sterilizable by gamma irradiation
US20200237620A1 (en) * 2017-10-06 2020-07-30 Sartorius Stedim Fmt Sas Protective containers for biopharmaceutical liquid bags
US20200253823A1 (en) * 2019-02-12 2020-08-13 Amgen Inc. Dosing systems and approaches
CN116602866A (zh) * 2023-04-24 2023-08-18 中国人民解放军陆军军医大学第二附属医院 一种可调节的输血袋固定装置

Similar Documents

Publication Publication Date Title
WO2025131618A1 (fr) Cassette pour dispositif d'administration de médicament
WO2025087694A1 (fr) Ensemble sac de médicament
WO2024217870A1 (fr) Ensemble sac de médicament
WO2025098784A1 (fr) Ensemble sac de médicament
WO2025149598A1 (fr) Sac en pellicule
WO2024052236A2 (fr) Sac souple blindé pour l'administration de médicaments radioactifs, cassette blindée d'administration de médicaments pour médicaments radioactifs et ensemble de tubes blindés pour l'administration de médicaments radioactifs
WO2025051546A1 (fr) Dispositif d'injection sur le corps et dispositif d'administration de médicament
WO2025223855A1 (fr) Ensemble boîtier-aiguille d'auto-injecteur
WO2024231105A1 (fr) Système d'administration de médicament et procédé associé
EP4646252A1 (fr) Dispositif d'administration de médicaments
WO2025098848A1 (fr) Ensemble pour dispositif d'administration de médicament
WO2025180828A1 (fr) Capuchon pour dispositif d'administration de médicament
EP4655022A1 (fr) Système d'administration de médicament
WO2025237664A1 (fr) Dispositif d'administration de médicament ayant un mécanisme de libération de tige de piston
WO2025153310A1 (fr) Auto-injecteur
WO2025113819A1 (fr) Dispositif d'administration de médicament
EP4646247A1 (fr) Dispositif d'administration de médicament
EP4646249A1 (fr) Dispositif d'administration de médicament
EP4646245A1 (fr) Système d'administration de médicament et procédé associé
WO2025113999A1 (fr) Dispositif d'administration de médicament
EP4584793A1 (fr) Ensemble de tubes de perfusion communiquant à courte portée et procédés d'utilisation
WO2024194029A1 (fr) Dispositif d'administration de médicament
WO2025153309A1 (fr) Auto-injecteur
EP4646251A1 (fr) Dispositif d'administration de médicament
JP2025537845A (ja) 医薬組成物容器の充填及びその後の閉鎖のためのアダプタ、並びにアダプタを有する容器

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24817530

Country of ref document: EP

Kind code of ref document: A1